RecruitingPhase 4NCT05829317

Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

Parenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility Study

Sponsor

Dr. Stephanie Sibley

Enrollment

200 participants

Start Date

Aug 20, 2023

Study Type

INTERVENTIONAL

Conditions

Critical Illness New Onset Atrial Fibrillation

Summary

A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Age ≥18 years;
Admitted to an ICU with one or more of the following:
Non-invasive ventilation (including CPAP, Bipap and high flow oxygen (\>10L/min) or invasive mechanical ventilation with an expected duration \>24 hours for respiratory failure (hypercarbic or hypoxic)
Vasopressor or inotropic support with an expected duration of \>24 hours
Cardiac arrest
Continuous cardiac monitoring.

Exclusion Criteria11

Receiving ICU intervention (Non-invasive ventilation (including high flow nasal canula), invasive mechanical ventilation or inotropic support) for \>18 hours
Receiving IMV for airway protection only (for example, isolated head trauma)
Active atrial fibrillation at the time of enrolment
On oral or continuous infusion of Amiodarone
Unlikely to survive \>24 hours or palliative patients
Cardiac surgery patients
Patients requiring parenteral magnesium therapy (e.g. pre-eclampsia, asthma)
Patients receiving dialysis
Positive pregnancy test (females \<50 years old)
Previously enrolled in this trial
Treating physician refuses enrollment